Drug Interactions between prednisone and Tylenol with Codeine
This report displays the potential drug interactions for the following 2 drugs:
- prednisone
- Tylenol with Codeine (acetaminophen/codeine)
Interactions between your drugs
No interactions were found between prednisone and Tylenol with Codeine. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
prednisone
A total of 633 drugs are known to interact with prednisone.
- Prednisone is in the drug class glucocorticoids.
-
Prednisone is used to treat the following conditions:
- Acute Lymphocytic Leukemia
- Adrenocortical Insufficiency
- Adrenogenital Syndrome
- Allergic Reactions
- Allergic Rhinitis
- Allergies
- Amyloidosis
- Ankylosing Spondylitis
- Aspiration Pneumonia
- Asthma
- Atopic Dermatitis
- Autoimmune Hemolytic Anemia
- Berylliosis
- Bullous Pemphigoid
- Bursitis
- Chorioretinitis
- Cluster Headaches
- Cogan's Syndrome
- Conjunctivitis, Allergic
- COPD
- Corneal Ulcer
- Crohn's Disease, Active
- Dermatitis Herpetiformis
- Dermatomyositis
- Diffuse Large B-Cell Lymphoma
- Eczema
- Epicondylitis, Tennis Elbow
- Erythroblastopenia
- Fibromyalgia
- Food Allergies
- Giant Cell Arteritis
- Gouty Arthritis
- Graft Versus Host Disease
- Herpes Zoster
- Herpes Zoster Iridocyclitis
- Hypercalcemia of Malignancy
- Immune Thrombocytopenia
- Immunoglobulin G4-Related Disease
- Immunosuppression
- Inflammatory Bowel Disease
- Inflammatory Conditions
- Interstitial Lung Disease
- Iridocyclitis
- Iritis
- Juvenile Rheumatoid Arthritis
- Keratitis
- Leukemia
- Lichen Planopilaris
- Lichen Planus
- Lichen Sclerosus
- Loeffler's Syndrome
- Lupus
- Lupus Nephritis
- Lymphoma
- Mixed Connective Tissue Disease
- Multiple Sclerosis
- Mycosis Fungoides
- Nephrotic Syndrome
- Neurosarcoidosis
- Optic Neuritis
- Osteoarthritis
- Pemphigoid
- Pemphigus
- Pharyngitis
- Polymyalgia Rheumatica
- Polymyositis/Dermatomyositis
- Psoriasis
- Psoriatic Arthritis
- Ramsay Hunt Syndrome
- Rheumatoid Arthritis
- Sarcoidosis
- Scleroderma
- Seborrheic Dermatitis
- Sinusitis
- Skin Rash
- Synovitis
- Systemic Sclerosis
- Thrombocytopenia
- Toxic Epidermal Necrolysis
- Tuberculosis, Extrapulmonary
- Tuberculous Meningitis
- Ulcerative Colitis, Active
- Uveitis, Posterior
Tylenol with Codeine
A total of 616 drugs are known to interact with Tylenol with Codeine.
- Tylenol with codeine is in the drug class narcotic analgesic combinations.
- Tylenol with codeine is used to treat the following conditions:
Drug and food/lifestyle interactions
codeine food/lifestyle
Applies to: Tylenol with Codeine (acetaminophen / codeine)
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur. In addition, alcohol may affect opioid release from sustained-release formulations.
GENERALLY AVOID: Grapefruit or grapefruit juice may increase the plasma concentrations of opioid analgesics by inhibiting CYP450 3A4-mediated metabolism of these agents, although the interaction has not been studied. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with opioid analgesics. Any history of alcohol or illicit drug use should be considered when prescribing an opioid analgesic, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with opioid analgesics should preferably avoid the consumption of grapefruit and grapefruit juice.
acetaminophen food/lifestyle
Applies to: Tylenol with Codeine (acetaminophen / codeine)
Ask your doctor before using acetaminophen together with ethanol (alcohol). This can cause serious side effects that affect your liver. Call your doctor immediately if you experience a fever, chills, joint pain or swelling, excessive tiredness or weakness, unusual bleeding or bruising, skin rash or itching, loss of appetite, nausea, vomiting, or yellowing of the skin or the whites of your eyes. If your doctor does prescribe these medications together, you may need a dose adjustment or special tests to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
acetaminophen food/lifestyle
Applies to: Tylenol with Codeine (acetaminophen / codeine)
Consumer information for this interaction is not currently available.
MONITOR: Smoking cessation may lead to elevated plasma concentrations and enhanced pharmacologic effects of drugs that are substrates of CYP450 1A2 (and possibly CYP450 1A1) and/or certain drugs with a narrow therapeutic index (e.g., flecainide, pentazocine). One proposed mechanism is related to the loss of CYP450 1A2 and 1A1 induction by polycyclic aromatic hydrocarbons in tobacco smoke; when smoking cessation agents are initiated and smoking stops, the metabolism of certain drugs may decrease leading to increased plasma concentrations. The mechanism by which smoking cessation affects narrow therapeutic index drugs that are not known substrates of CYP450 1A2 or 1A1 is unknown. The clinical significance of this interaction is unknown as clinical data are lacking.
MANAGEMENT: Until more information is available, caution is advisable if smoking cessation agents are used concomitantly with drugs that are substrates of CYP450 1A2 or 1A1 and/or those with a narrow therapeutic range. Patients receiving smoking cessation agents may require periodic dose adjustments and closer clinical and laboratory monitoring of medications that are substrates of CYP450 1A2 or 1A1.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.